Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Loxo buys BTK inhibitor

by Lisa M. Jarvis
August 7, 2017 | A version of this story appeared in Volume 95, Issue 32

Loxo Oncology will pay Redx Pharma $40 million for the full rights to an inhibitor of BTK, an enzyme involved in B-cell development. Imbruvica, a B-cell cancer treatment marketed by AbbVie, and other BTK inhibitors in clinical studies all covalently bind to the enzyme, a mechanism Loxo argues drives resistance to those molecules through a specific mutation. By reversibly binding to BTK, Redx’s lead molecule, RXC005, could help people with cancer who no longer respond to the covalent inhibitors. Now known as LOXO-305, the compound is expected to begin human trials next year.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.